Peroxisome proliferator-activated receptor-alpha selective ligand reduces adiposity, improves insulin sensitivity and inhibits atherosclerosis in LDL receptor-deficient mice.
Fenofibrate, a selective (1)PPAR-alpha activator, is prescribed to treat human dyslipidemia. The aim of this study was to delineate the mechanism of fenofibrate-mediated reductions in adiposity, improvements in insulin sensitivity, and lowering of triglycerides (TG) and free fatty acids (FFA) and to investigate if these favorable changes are related to the inhibition of lipid deposition in the aorta. To test this hypothesis we used male LDLr deficient mice that exhibit the clinical features of metabolic syndrome X when fed a high fat high cholesterol (HF) diet. LDLr deficient mice fed HF diet and simultaneously treated with fenofibrate (100 mg/kg body weight) prevented development of obesity, lowered serum triglycerides and cholesterol, improved insulin sensitivity, and prevented accumulation of lipids in the aorta. Lowering of circulating lipids occurred via down-regulation of lipogenic genes, including fatty acid synthase, acetyl CoA carboxylase and diacyl glycerol acyl transferase-2, concomitant with decreased liver TG and cholesterol, and TG output rate. Fenofibrate also suppressed liver apoCIII mRNA levels and markedly increased lipoprotein lipase mRNA levels, known to enhance serum TG catabolism. In addition, fenofibrate profoundly reduced epididymal fat and mesenteric fat mass to the levels seen in lean mice. The reductions in body weight were associated with elevation of hepatic uncoupling protein 2 (UCP2) mRNA, a concomitant increase in the ketone body formation, and improved insulin sensitivity associated with tumor necrosis factor-alpha reductions and phosphoenol pyruvate carboxykinase down-regulation. These results demonstrate that fenofibrate improves lipid abnormalities partly via inhibition of TG production and partly via clearance of TG-rich apoB particles by elevating LPL and reduced apoCIII. The prevention of obesity development occurred via energy expenditure. Fenofibrate-mediated hypolipidemic effects together with improved insulin sensitivity and loss of adiposity led to the reductions in the aortic lipid deposition by inhibiting early stages of atherosclerosis possibly via vascular cell adhesion molecule-1 (VCAM-1) modulation. These results suggest that potent PPAR-alpha activators may be useful in the treatment of syndrome X.
CloneGen Biotechnology, Ann Arbor, MI, USA. raiajit.srivastava@bms.com
Rai Ajit K
RA
Srivastava
Ravi
R
Jahagirdar
Salman
S
Azhar
Somesh
S
Sharma
Charles L
CL
Bisgaier
D050154:Adiposity / Q000187:drug effects*; D000818:Animals; D001011:Aorta / Q000473:pathology; D003324:Coronary Artery Disease / Q000188:drug therapy*; D004036:Diet, Atherogenic; D004734:Energy Metabolism / Q000187:drug effects; D011345:Fenofibrate / Q000494:pharmacology*; D005943:Gluconeogenesis / Q000187:drug effects; D006937:Hypercholesterolemia / Q000188:drug therapy; D015228:Hypertriglyceridemia / Q000188:drug therapy; D007328:Insulin / Q000378:metabolism; D007333:Insulin Resistance; D020738:Leptin / Q000378:metabolism; D008024:Ligands; D050356:Lipid Metabolism / Q000187:drug effects; D008055:Lipids / Q000097:blood; D050155:Lipogenesis / Q000187:drug effects / Q000235:genetics; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D008297:Male; D024821:Metabolic Syndrome / Q000188:drug therapy; D051379:Mice; D008810:Mice, Inbred C57BL; D009765:Obesity / Q000188:drug therapy / Q000517:prevention & control; D047493:PPAR alpha / Q000378:metabolism / Q000502:physiology*; D011973:Receptors, LDL / Q000172:deficiency*; D014280:Triglycerides / Q000378:metabolism; D015430:Weight Gain / Q000187:drug effects
D007328:Insulin; D020738:Leptin; D008024:Ligands; D008055:Lipids; D047493:PPAR alpha; D011973:Receptors, LDL; D014280:Triglycerides; D011345:Fenofibrate